BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra’s novel therapeutic approaches to treating anterior and posterior segment ocular disease at the Eyecelerator 2020 Virtual Conference on Friday, November 6, 2020. Dr. Brady’s presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as part of Company Showcase III, “Advancing T

Agilent Technologies Inc. (NYSE: A) announced today a collaboration with SGS has resulted in a new GC/TQ method, the SGS AXYS Method 16130, approved by the US EPA as an alternative method for the future regulation and detection of dioxins. Dioxins are a group of chemical compounds that are considered persistent environmental pollutants and su

Arcturus Therapeutics Holdings Inc. announced that the Company will be presenting at upcoming investor and scientific conferences virtually:

Samsung Biologics’ Virtual Exhibition Hall was recently recognized for its highly interactive digital capabilities and virtual reality technology to connect with clients around the world.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in three upcoming investor conferences.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2020 financial results after the market close on Thursday, November 12, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. Investors interested in listen

vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with type 2 diabetes (NCT03980730). The data demonstrate that the patients enrolled in Elevage (n=43) have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes (T2D) subgroup (NCT02080364) (

Stryker (NYSE: SYK) announced today that all required regulatory approvals have been obtained for the previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) by Stryker B.V., an indirect, wholly owned subsidiary of Stryker. The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical. “We are pleased

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial resu